Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Br J Pharmacol ; 153(3): 609-19, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18059322

ABSTRACT

BACKGROUND AND PURPOSE: Compounds that activate both NOP and mu-opioid receptors might be useful as analgesics and drug abuse medications. Studies were carried out to better understand the biological activity of such compounds. EXPERIMENTAL APPROACH: Binding affinities were determined on membranes from cells transfected with NOP and opioid receptors. Functional activity was determined by [(35)S]GTPgammaS binding on cell membranes and using the mouse vas deferens preparation in vitro and the tail flick antinociception assay in vivo. KEY RESULTS: Compounds ranged in affinity from SR14150, 20-fold selective for NOP receptors, to buprenorphine, 50-fold selective for mu-opioid receptors. In the [(35)S]GTPgammaS assay, SR compounds ranged from full agonist to antagonist at NOP receptors and most were partial agonists at mu-opioid receptors. Buprenorphine was a low efficacy partial agonist at mu-opioid receptors, but did not stimulate [(35)S]GTPgammaS binding through NOP. In the mouse vas deferens, each compound, except for SR16430, inhibited electrically induced contractions. In each case, except for N/OFQ itself, the inhibition was due to mu-opioid receptor activation, as determined by equivalent results in NOP receptor knockout tissues. SR14150 showed antinociceptive activity in the tail flick test, which was reversed by the opioid antagonist naloxone. CONCLUSIONS AND IMPLICATIONS: Compounds that bind to both mu-opioid and NOP receptors have antinociceptive activity but the relative contribution of each receptor is unclear. These experiments help characterize compounds that bind to both receptors, to better understand the mechanism behind their biological activities, and identify new pharmacological tools to characterize NOP and opioid receptors.


Subject(s)
Pain/drug therapy , Receptors, Opioid, mu/drug effects , Receptors, Opioid/drug effects , Analgesics, Opioid/pharmacology , Animals , Buprenorphine/pharmacology , CHO Cells , Cell Membrane/metabolism , Cricetinae , Cricetulus , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Indoles/pharmacology , Ligands , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Pain Measurement , Protein Binding , Receptors, Opioid/genetics , Receptors, Opioid/metabolism , Receptors, Opioid, mu/metabolism , Vas Deferens/drug effects , Vas Deferens/metabolism , Nociceptin Receptor
2.
J Pept Res ; 64(3): 87-94, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15317498

ABSTRACT

Nociceptin/orphanin FQ (N/OFQ) is a 17 amino acid peptide that is the endogenous ligand for the G-protein coupled receptor ORL1 (NOP), a member of the opioid receptor family. Although it is clear that this receptor system is involved in a variety of physiologic functions, including analgesia, the precise actions of N/OFQ remain largely uncharacterized. One reason for this has been limited number of high-affinity ligands to NOP, and particularly the lack of availability of useful specific antagonists. Herein, we describe the pharmacologic activity of a series of modified amino acid containing modifications of the hexapeptide Ac-RYYRWR-NH2, with high affinity for NOP. These compounds were tested for binding affinity using [3H]N/OFQ binding to human NOP in CHO cells, and functional activity by measuring stimulation of [35S]GTPgammaS-binding in CHO cell membranes. These studies suggest that each Arg of the hexapeptide is required to maintain high-binding affinity. The peptide maintains high affinity if the Tyr2 or Tyr3 are modified, but at least one of these residues must maintain its hydroxyl group or there is a large decrease in intrinsic activity of the peptide.


Subject(s)
Oligopeptides/chemistry , Oligopeptides/pharmacology , Receptors, Opioid/drug effects , Animals , Arginine/chemistry , CHO Cells , Cricetinae , DNA, Complementary/genetics , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Humans , In Vitro Techniques , Kinetics , Ligands , Male , Mice , Oligopeptides/metabolism , Opioid Peptides/chemistry , Opioid Peptides/metabolism , Receptors, Opioid/genetics , Receptors, Opioid/metabolism , Recombinant Proteins/drug effects , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Structure-Activity Relationship , Transfection , Tyrosine/chemistry , Vas Deferens/drug effects , Vas Deferens/physiology , Nociceptin Receptor , Nociceptin
3.
Life Sci ; 69(15): 1775-82, 2001 Aug 31.
Article in English | MEDLINE | ID: mdl-11665839

ABSTRACT

HS 378 is a recently developed indolomorphinan with high selectivity and antagonist potency at the delta-opioid receptor. The present study was performed to characterize the opioid binding properties and pharmacological and immunological activity of HS 378 and to compare them with those of two well-known delta-opioid receptor antagonists, naltrindole (NTI) and naltriben (NTB). In vitro opioid receptor binding profiles were determined in rat brain homogenates. HS 378 showed 4.7- and 2.4-fold higher mu/delta selectivity compared to NTI and NTB, respectively. In the [35S]GTPgammaS functional assay carried out in cell lines expressing cloned human opioid receptors, HS 378 was found to be a pure delta-opioid receptor antagonist. In vitro, exposure of HS 378 resulted in an apparent dose-related suppression of concanavalin A induced rat T-lymphocyte proliferation with an IC50 value of 0.54 microM. NTI showed also immunosuppression with an IC50 value of 6.93 microM, whereas NTB had no effect. The IC50 of HS 378 was 13 times lower than that of NTI and 8 times higher than that of cyclosporin A. Taken together, our findings indicate that the small molecule HS 378 has properties that may be of therapeutic value in the setting of human inflammatory diseases.


Subject(s)
Lymphocyte Activation/drug effects , Naltrexone/analogs & derivatives , Naltrexone/metabolism , Naltrexone/pharmacology , Narcotic Antagonists/metabolism , Narcotic Antagonists/pharmacology , Receptors, Opioid, delta/antagonists & inhibitors , Animals , Brain/metabolism , Cells, Cultured , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, delta/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
4.
J Urol ; 165(3): 1004-9, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11176530

ABSTRACT

PURPOSE: Zaprinast, dipyridamole and sildenafil were injected into the corpora cavernosa of cats to determine whether changes in the steady state level of cyclic guanosine monophosphate (cGMP) induced by inhibiting type 5 phosphodiesterase would cause an erectile response. MATERIALS AND METHODS: Increases in intracavernous pressure, penile length and erectile response duration were determined after intracavernous injection of the type 5 cGMP specific phosphodiesterase inhibitors zaprinast, dipyridamole and sildenafil as well as combined zaprinast and prostaglandin E1 (PGE1), and zaprinast and sodium nitroprusside. Systemic arterial pressure was concurrently assessed in these experiments. All responses to phosphodiesterase inhibitors were compared to a control triple drug combination of 1.65 mg papaverine, 0.5 microg PGE1 and 25 microg phentolamine. RESULTS: Each selective type 5 phosphodiesterase inhibitor caused dose related increases in intracorporeal pressure and penile length. However, none of the compounds was as effective as the control drug combination of papaverine, phentolamine and PGE1. Combining zaprinast with sodium nitroprusside led to further increases in pressure and erectile response duration that more closely resembled the control drug response. Combining zaprinast with PGE1 led to a response that was indistinguishable from the control response. CONCLUSIONS: The results of these feline studies establish that administering a type 5 phosphodiesterase inhibitor without concomitant administration of a nitric oxide donor or stimulation of the cavernous nerves may have a direct effect on the erectile response. These data also suggest that combining a selective type 5 phosphodiesterase inhibitor with PGE1 may be highly effective local therapy for erectile dysfunction and an acceptable alternative to other current forms of treatment.


Subject(s)
Nitroprusside/pharmacology , Penile Erection/drug effects , Phosphodiesterase Inhibitors/pharmacology , Purinones/pharmacology , Vasodilator Agents/pharmacology , Alprostadil/pharmacology , Animals , Cats , Dipyridamole/pharmacology , Dose-Response Relationship, Drug , Male , Piperazines/pharmacology , Purines , Sildenafil Citrate , Sulfones
6.
J Med Chem ; 43(9): 1852-7, 2000 May 04.
Article in English | MEDLINE | ID: mdl-10794701

ABSTRACT

A series of ethers of orvinol and isoorvinol has been prepared and evaluated in opioid receptor binding and in vitro functional assays. The most striking finding was the very large difference in kappa-opioid receptor activity between the diastereomeric ethyl ethers: 46-fold in binding, 150-fold in GPI, and 900-fold in the [(35)S]GTPgammaS assay in favor of the (R)-diastereomer. Additionally in the (R)-series there was a 700-fold increase in kappa-agonist potency in the [(35)S]GTPgammaS assay when OEt was replaced by OBn. The data can be explained in a triple binding site model: an H-bonding site, a lipophilic site, and an inhibitory site with which the 20-Me group in the (S)-ethers may interact. It appears that kappa-agonist binding of the orvinols avoids the inhibitory site in the intramolecular H-bonded conformation.


Subject(s)
Analgesics, Opioid/pharmacology , Hydroxamic Acids/chemical synthesis , Narcotics/pharmacology , Analgesics, Opioid/chemistry , Animals , Binding, Competitive/drug effects , CHO Cells , Cell Membrane/drug effects , Cell Membrane/metabolism , Cricetinae , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Guinea Pigs , Humans , Hydroxamic Acids/pharmacology , In Vitro Techniques , Magnetic Resonance Spectroscopy , Narcotics/chemical synthesis , Narcotics/chemistry , Spectrophotometry, Infrared , Stereoisomerism
8.
J Pharmacol Exp Ther ; 283(2): 735-41, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9353393

ABSTRACT

Fifteen hexapeptides having high affinity for the opioid-like receptor ORL1 were identified from a combinatorial library containing more than 52 million different hexapeptides. The five compounds with the highest affinity were characterized further by use of a variety of in vitro models. Binding studies indicated that these five peptides have affinity for ORL1 in the nanomolar range, similar to the recently discovered endogenous ligand called nociceptin and orphanin FQ (N/OFQ). The activity of these compounds was investigated in three different assays: stimulation of [35S]GTPgammaS binding and inhibition of forskolin-stimulated cAMP accumulation in Chinese hamster ovary cells transfected with ORL1, and inhibition of electrically induced contractions in the mouse vas deferens. In each assay, the five hexapeptides acted as partial agonists. The EC50 values for stimulation of [35S]GTPgammaS binding and inhibition of cAMP accumulation were in the range of that for N/OFQ, but maximal effects ranged from 70 to 90% of N/OFQ in the cAMP assay, and 30 to 60% of N/OFQ in the GTPgammaS assay. The positive hexapeptides identified were found to have minimal structural similarity to N/OFQ. The peptides are positively charged, which could enable them to bind to the negatively charged second extracellular loop thought to be a likely binding site for N/OFQ.


Subject(s)
Oligopeptides/metabolism , Receptors, Opioid/metabolism , Amino Acid Sequence , Animals , CHO Cells , Cricetinae , Cyclic AMP/biosynthesis , Male , Mice , Molecular Sequence Data , Oligopeptides/pharmacology , Rats , Vas Deferens/drug effects , Nociceptin Receptor
9.
Life Sci ; 60(15): PL235-9, 1997.
Article in English | MEDLINE | ID: mdl-9096250

ABSTRACT

Guinea pig ileum longitudinal muscle/myenteric plexus preparations contain functional mu- and kappa-opioid receptors. A preparation with blocked kappa receptors was obtained by pretreating guinea pigs with 0.1-10.0 mg/kg intraperitoneal doses of a new kappa-selective affinity label, DIPPA (2-(3,4-dichlorophenyl)-N-methyl-N-[1S-1-(-3-isothiocyanatophenyl)-2-(-1 -pyrrolidinyl) ethyl] acetamide). Determination of IC50 values for the mu-selective agonist DAMGO ([D-Ala2,MePhe4,Gly(ol)5]-enkephalin) and the kappa-selective agonist U 69,593 ([5alpha,7alpha,8beta]-(+)-N-methyl-N-[7-(1-pyrrolidin yl)-1-oxaspiro-(4,5)-dec-8-yl]) showed that 0.5 mg/kg DIPPA at 48 h produced reliable, near-complete blockade of kappa-opioid activity but a minimal shift for kappa-opioid agonism. This new assay should be useful for studying mixed agonists/antagonists that produce strong kappa-opioid receptor agonism, which prevents determination of mu-opioid receptor antagonism.


Subject(s)
Acetamides/pharmacology , Affinity Labels/pharmacology , Benzeneacetamides , Ileum/metabolism , Isothiocyanates/pharmacology , Narcotic Antagonists/pharmacology , Receptors, Opioid, kappa/drug effects , Receptors, Opioid, mu/metabolism , Analgesics/pharmacology , Animals , Enkephalin, Ala(2)-MePhe(4)-Gly(5)- , Enkephalins/pharmacology , Guinea Pigs , Male , Muscle, Smooth/metabolism , Pyrrolidines/pharmacology , Receptors, Opioid, kappa/metabolism
10.
Synapse ; 24(2): 193-201, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8890461

ABSTRACT

Naloxone benzoylhydrazone (NalBzoH) has proved a valuable tool in the investigation of opioid receptor subtypes. In the present study, we have examined a series of derivatives of NalBzoH in which substitutions have been made on the benzoyl ring. Overall, we see dramatic effects on the binding affinities of derivatives against the various opioid receptor subtypes. Although the range of affinities against the mu receptors is quite modest, ranges of the others vary almost 30-fold for kappa 3, 50-fold for kappa 1 and 100-fold for delta and kappa 2 binding. Few substituted derivatives display greater affinity than NalBzoH for any of the receptors, except for delta sites where several derivatives have affinities almost tenfold greater than NalBzoH. Along with the wide variations in affinity, the compounds also appear to exhibited widely divergent activities in traditional bioassays.


Subject(s)
Binding, Competitive , Naloxone/analogs & derivatives , Naloxone/metabolism , Receptors, Opioid/drug effects , Animals , Cattle , Guinea Pigs
11.
Eur J Pharmacol ; 302(1-3): R1-2, 1996 Apr 29.
Article in English | MEDLINE | ID: mdl-8791013

ABSTRACT

The recently discovered neuropeptide nociceptin was found to inhibit electrically induced contractions of the mouse vas deferens. Nociceptin and its 14-Tyr analog were each partial agonists, but with high affinity (ED50 of 20 nM). This activity was not opioid in nature, as it was not inhibited by either selective or non-selective opiate antagonists.


Subject(s)
Muscle Contraction/drug effects , Opioid Peptides/pharmacology , Vas Deferens/drug effects , Animals , Dose-Response Relationship, Drug , Electrophysiology , Male , Mice , Narcotic Antagonists/pharmacology , Opioid Peptides/antagonists & inhibitors , Rats , Receptors, Opioid/agonists , Nociceptin
12.
Eur J Pharmacol ; 277(2-3): 257-63, 1995 Apr 24.
Article in English | MEDLINE | ID: mdl-7493617

ABSTRACT

On the basis of its in vivo activity and binding affinity, naloxone benzoylhydrazone has been characterized as a kappa 3-opioid receptor agonist and a mu-opioid receptor antagonist. This paper continues its pharmacological characterization with the help of isolated tissue preparations. Naloxone benzoylhydrazone was found to have partial agonist activity in the guinea pig ileum longitudinal muscle/myenteric plexus preparation. As an antagonist, naloxone benzoylhydrazone is similar to naloxone, with pA2 values of 8.8, 7.8, and 7.8 for mu-, delta-, and kappa 1-opioid receptors, respectively. Its agonist activity in the guinea pig ileum preparation was not influenced by beta-funaltrexamine treatment but was reversed by the selective kappa-opioid receptor antagonist nor-binaltorphimine and by the irreversible kappa 1-opioid receptor blocker UPHIT (1S,2S)-trans-2-isothiocyanato-4,5-dichloro-N-methyl-N-[2-(1- pyrrolidinyl)-cyclohexyl] benzeneacetamide. The presence of kappa 3-opioid receptors could not be demonstrated by [3H]naloxone benzoylhydrazone binding in the guinea pig ileum longitudinal muscle/myenteric plexus preparation. From these studies it is concluded that the partial agonist activity of naloxone benzoylhydrazone in this bioassay is probably due to the activation of the kappa 1-opioid receptors.


Subject(s)
Benzeneacetamides , Muscle, Smooth/drug effects , Myenteric Plexus/drug effects , Naloxone/analogs & derivatives , Narcotic Antagonists/pharmacology , Animals , Binding, Competitive , Computer Simulation , Cyclohexanes/pharmacology , Guinea Pigs , Ileum/drug effects , Ileum/metabolism , In Vitro Techniques , Male , Muscle, Smooth/metabolism , Myenteric Plexus/metabolism , Naloxone/metabolism , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Pyrrolidines/pharmacology , Radioligand Assay , Receptors, Opioid, delta/drug effects , Receptors, Opioid, delta/metabolism , Receptors, Opioid, kappa/drug effects , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/drug effects , Receptors, Opioid, mu/metabolism
13.
Eur J Pharmacol ; 231(2): 251-8, 1993 Feb 09.
Article in English | MEDLINE | ID: mdl-8095898

ABSTRACT

The presence of kappa-opioid receptor subtypes has been clearly established in guinea pig brain. Using [3H]bremazocine in the presence of reversible blockers of mu, delta and kappa 1 receptors, two additional binding sites can be determined in guinea pig brain membranes. The site with higher affinity for the opioid ligands represents kappa 2, while the other site has low affinity and is poorly characterized. The kappa 2 site has high affinity for ethylketocyclazocine and other benzomorphans, as well as for the dynorphin gene products tested. The dynorphin analogs have no appreciable affinity for the low affinity site, so this site should not be called a kappa receptor. With an appropriate membrane preparation, kappa 2 binding can also be demonstrated in the guinea pig ileum. Binding affinities for selected ligands at kappa 2 in guinea pig ileum membranes are very similar to affinities found in brain membranes.


Subject(s)
Brain Chemistry/physiology , Ileum/metabolism , Receptors, Opioid, kappa/metabolism , Analgesics/metabolism , Animals , Benzomorphans/metabolism , Brain Chemistry/drug effects , Dynorphins/analogs & derivatives , Dynorphins/pharmacology , Ethylketocyclazocine/pharmacology , Guanylyl Imidodiphosphate/pharmacology , Guinea Pigs , Ileum/drug effects , In Vitro Techniques , Kinetics , Ligands , Male , Membranes/metabolism , Myenteric Plexus/drug effects , Myenteric Plexus/metabolism , Receptors, Opioid, kappa/drug effects
14.
Eur J Pharmacol ; 212(2-3): 283-6, 1992 Mar 03.
Article in English | MEDLINE | ID: mdl-1318215

ABSTRACT

On the basis of their in vivo activity and binding affinity, nalorphine and (-)SKF 10,047 were classified as mixed agonist/antagonist compounds. However, in isolated tissue preparations without a selective antagonist to block their agonist effect, the characterization of these compounds and the determination of their antagonist activity were very difficult. Nor-binaltorphimine, a selective kappa-opioid receptor antagonist, was used in the longitudinal muscle preparations of the guinea pig ileum to block the kappa-agonist activity of nalorphine and (-)SKF 10,047. In the absence of their kappa-agonist activity, we were able to determine the mu-antagonist activity using the mu-selective agonist DAMGO ([D-Ala2,N-Me-Phe4,Gly-ol5]enkephalin). The pA2 values for nalorphine and (-)SKF 10,047 were 7.50 and 7.69, respectively.


Subject(s)
Muscle, Smooth/drug effects , Receptors, Opioid/drug effects , Animals , Ethylketocyclazocine/pharmacology , Guinea Pigs , Ileum/drug effects , Ileum/innervation , In Vitro Techniques , Male , Muscle Contraction/drug effects , Nalorphine/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Phenazocine/analogs & derivatives , Phenazocine/pharmacology , Receptors, Opioid, kappa , Receptors, Opioid, mu
SELECTION OF CITATIONS
SEARCH DETAIL
...